全文获取类型
收费全文 | 1688篇 |
免费 | 129篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 45篇 |
妇产科学 | 60篇 |
基础医学 | 233篇 |
口腔科学 | 39篇 |
临床医学 | 184篇 |
内科学 | 327篇 |
皮肤病学 | 36篇 |
神经病学 | 126篇 |
特种医学 | 44篇 |
外科学 | 263篇 |
综合类 | 38篇 |
预防医学 | 128篇 |
眼科学 | 73篇 |
药学 | 140篇 |
中国医学 | 16篇 |
肿瘤学 | 69篇 |
出版年
2024年 | 5篇 |
2023年 | 43篇 |
2022年 | 67篇 |
2021年 | 93篇 |
2020年 | 68篇 |
2019年 | 89篇 |
2018年 | 108篇 |
2017年 | 78篇 |
2016年 | 92篇 |
2015年 | 83篇 |
2014年 | 105篇 |
2013年 | 117篇 |
2012年 | 165篇 |
2011年 | 156篇 |
2010年 | 88篇 |
2009年 | 59篇 |
2008年 | 80篇 |
2007年 | 77篇 |
2006年 | 70篇 |
2005年 | 44篇 |
2004年 | 35篇 |
2003年 | 22篇 |
2002年 | 14篇 |
2001年 | 10篇 |
2000年 | 3篇 |
1999年 | 15篇 |
1998年 | 5篇 |
1997年 | 4篇 |
1996年 | 3篇 |
1995年 | 2篇 |
1993年 | 1篇 |
1992年 | 4篇 |
1991年 | 4篇 |
1990年 | 3篇 |
1989年 | 3篇 |
1988年 | 2篇 |
1987年 | 2篇 |
1986年 | 2篇 |
1985年 | 3篇 |
1984年 | 1篇 |
1979年 | 1篇 |
1969年 | 1篇 |
1968年 | 1篇 |
排序方式: 共有1828条查询结果,搜索用时 15 毫秒
61.
Buskbjerg Cecilie R. Zachariae Robert Agerbæk Mads Gravholt Claus H. Haldbo-Classen Lene Hosseini S. M. Hadi Amidi Ali 《Brain imaging and behavior》2022,16(1):199-210
Brain Imaging and Behavior - A higher incidence of cognitive impairment (CI) has previously been reported among orchiectomized testicular cancer patients (TCPs), but little is known about the... 相似文献
62.
63.
64.
65.
Mehdi Farokhnia Maryam Sabzabadi Hossein Pourmahmoud Mohammad-Reza Khodaie-Ardakani Seyed-Mohammad-Reza Hosseini Habibeh Yekehtaz Mina Tabrizi Farzin Rezaei Bahman Salehi Shahin Akhondzadeh 《Psychopharmacology》2014,231(3):533-542
Rationale
Several recent studies have focused on glutamate modulating agents for symptoms relief in schizophrenia, especially negative symptoms which are resistant to conventional therapies.Objectives
We aimed to assess the efficacy and tolerability of riluzole, an anti-glutamate agent with neuroprotective properties, as an adjunct to risperidone in improving negative symptoms of schizophrenia.Methods
In this randomized double-blind placebo-controlled parallel-group study, 50 patients with chronic schizophrenia and a score of ≥20 on the negative subscale of positive and negative syndrome scale (PANSS) were enrolled in the active phase of their illness. Participants were equally randomized to receive riluzole (100 mg/day) or placebo in addition to risperidone (up to 6 mg/day) for 8 weeks. Participants were rated by PANSS every 2 weeks. The primary outcome of this study was the difference in the decrease of PANSS negative subscale score from baseline to the study endpoint between the two groups.Results
By the study endpoint, riluzole-treated patients showed significantly greater improvement in the negative symptoms (P?<?0.001) as well as the PANSS total and general psychopathology subscale scores (P?=?0.001 and P?<?0.001; respectively) compared to the placebo group. Treatment group was the only significant predictor of changes in negative symptom in this trial (β?=??0.56, P?<?0.001). No significant difference was observed between two groups in the frequency of side effects.Conclusion
These preliminary findings suggest that riluzole may be a safe and effective medication for the treatment of negative symptoms in patients with chronic schizophrenia. Further research and replication of study findings is warranted.Clinical trial registry name and registration number
Iranian registry of clinical trials www.irct.ir, IRCT201107281556N26 相似文献66.
67.
A Novel Protocol to Differentiate Induced Pluripotent Stem Cells by Neuronal microRNAs to Provide a Suitable Cellular Model
下载免费PDF全文
![点击此处可从《Chemical biology & drug design》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Mehrak Zare Masoud Soleimani Abolfazl Akbarzadeh Behnaz Bakhshandeh Seyed Hamid Aghaee‐Bakhtiari Nosratollah Zarghami 《Chemical biology & drug design》2015,86(2):232-238
Neurodegenerative diseases are one of the most challenging subjects in medicine. Investigation of their underlying genetic or epigenetic factors is hampered by lack of suitable models. Patient‐specific induced pluripotent stem cells (iPS cells) represent a valuable approach to provide a proper model for poorly understood mechanisms of neuronal diseases and the related drug screenings. miR‐124 and miR‐128 are the two brain‐enriched miRNAs with different time‐points of expression during neuronal development. Herein, we transduced human iPS cells with miR‐124 and miR‐128 harboring lentiviruses sequentially. The transduced plasmids contained GFP and puromycin antibiotic‐resistant genes for easier selection and identification. Morphological assessment and immunocytochemistry (overexpressions of beta‐tubulin and neuron‐specific enolase) confirmed that induced hiPS cells by miR‐124 and miR‐128 represent similar characteristics to those of mature neurons. In addition, the upregulation of neuron‐specific enolase, beta‐tubulin, Map2, GFAP, and BDNF was detected by quantitative real‐time PCR. In conclusion, it seems that our novel protocol remarks the combinatorial effect of miR‐124 and miR‐128 on neural differentiation in the absence of any extrinsic factor. Moreover, such cellular models could be used in personalized drug screening and applied for more effective therapies. 相似文献
68.
Up Regulation of Liver-enriched Transcription Factors HNF4a and HNF6 and Liver-Specific MicroRNA (miR-122) by Inhibition of Let-7b in Mesenchymal Stem Cells
下载免费PDF全文
![点击此处可从《Chemical biology & drug design》网站下载免费的PDF全文](/ch/ext_images/free.gif)
69.
70.
Niklas Lonnemann Shirin Hosseini Carlo Marchetti Damaris B. Skouras Davide Stefanoni Angelo DAlessandro Charles A. Dinarello Martin Korte 《Proceedings of the National Academy of Sciences of the United States of America》2020,117(50):32145
Numerous studies demonstrate that neuroinflammation is a key player in the progression of Alzheimer’s disease (AD). Interleukin (IL)-1β is a main inducer of inflammation and therefore a prime target for therapeutic options. The inactive IL-1β precursor requires processing by the the nucleotide-binding oligomerization domain-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome into a mature and active form. Studies have shown that IL-1β is up-regulated in brains of patients with AD, and that genetic inactivation of the NLRP3 inflammasome improves behavioral tests and synaptic plasticity phenotypes in a murine model of the disease. In the present study, we analyzed the effect of pharmacological inhibition of the NLRP3 inflammasome using dapansutrile (OLT1177), an oral NLRP3-specific inhibitor that is safe in humans. Six-month-old WT and APP/PS1 mice were fed with standard mouse chow or OLT1177-enriched chow for 3 mo. The Morris water maze test revealed an impaired learning and memory ability of 9-mo-old APP/PS1 mice (P = 0.001), which was completely rescued by OLT1177 fed to mice (P = 0.008 to untreated APP/PS1). Furthermore, our findings revealed that 3 mo of OLT1177 diet can rescue synaptic plasticity in this mouse model of AD (P = 0.007 to untreated APP/PS1). In addition, microglia were less activated (P = 0.07) and the number of plaques was reduced in the cortex (P = 0.03) following NLRP3 inhibition with OLT1177 administration. We also observed an OLT1177 dose-dependent normalization of plasma metabolic markers of AD to those of WT mice. This study suggests the therapeutic potential of treating neuroinflammation with an oral inhibitor of the NLRP3 inflammasome.Alzheimer’s disease (AD) and other related neurodegenerative diseases leading to dementia represent an enormous burden for the society and health economies. AD patients suffer progressive cognitive and functional deficits often for many years, which result in a heavy burden to patients, families, and the public health system. In fact, in 2015 an estimated 46.8 million people worldwide were living with dementia, which could extend to 131.5 million by 2050 (1). Rising prevalence and mortality rates in combination with a lack of effective treatments lead to enormous costs to society. Research on AD in the last decades has focused on the pathological hallmarks and cellular deposits of amyloid-β (Aβ) peptides and neurofibrils (2). Recently, there has been increased evidence supporting a central role of the immune system in the progression or even the origin of the disease (3–5). In this respect, it is noteworthy that it has been known since 1989 that levels of interleukin (IL)-1β, one of the main mediators of innate immune response, are elevated in brains of patients with AD and can be associated with the progression and onset of AD (6–11). Additionally, it was shown that the nucleotide-binding oligomerization domain-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome (12, 13), a multisubunit complex important for the maturation of IL-1β, is activated by Aβ peptides, leading to an overproduction of IL-1β, neuroinflammation, and cognitive impairment (14, 15). Inhibition of the NLRP3 inflammasome and the subsequent reduced IL-1β production can be linked to a change in the phenotype of microglia, the innate immune cells in the brain. Heneka et al. (16) pointed out the important role of the NLRP3 inflammasome/caspase-1 axis in AD pathogenesis by demonstrating significant improvements (e.g., in cognition) in APP/PS1 mice (a mouse model for AD) when crossed with NLRP3−/− animals. The APP/PS1 mice express a human amyloid precursor protein (APP) and human presenilin-1 (PS1), leading to the accumulation of Aβ peptides, neuroinflammation, and cognitive impairment (17).OLT1177 (rINN: dapansutrile) is a new chemical entity small molecule that specifically targets the NLRP3 inflammasome and prevents the activation of caspase-1 and the maturation and release of IL-1β (18). OLT1177 has been shown to be well tolerated in animals and humans (18) and is currently in phase 2 clinical studies for the treatment of inflammatory conditions, such as osteoarthritis (topical gel dosage form) and inflammatory diseases, such as acute gout flare (oral capsule dosage form), among other diseases (19).In this study, we used the APP/PS1 mouse model of AD to investigate the effects of OLT1177 as an acute, oral pharmacological intervention (17). Six-month-old WT and APP/PS1ΔE9 mice consumed ad libitum OLT1177 in feed pellets (∼0, 500, or 1,000 mg/kg/d based on feed concentrations of 0, 3.75 or 7.5 g of OLT1177 per kilogram of feed; hereafter referred to as 3.75 or 7.5 g/kg OLT1177) for the treatment duration of 3 mo. APP/PS1 mice treated with OLT1177 showed rescue effects in various assessments, ranging from improved cognitive function to overall reduction in proinflammatory cytokines in the brain, suggesting the potential benefits of pharmaceutically blocking NLRP3 signaling in AD. 相似文献